Ovarian Cancer Clinical Trials & Research

Doctors at Memorial Sloan Kettering are constantly working to improve treatment for ovarian cancer through clinical trials. Participating in a clinical trial may give you access to treatments that are not widely available elsewhere, and may offer additional options if your cancer has returned after standard treatment.

Our doctors lead clinical trials that test new drugs and drug combinations, surgical approaches, and strategies for preserving quality of life during and after treatment. We can help determine which clinical trials are right for you.

The following clinical trials for ovarian cancer are currently enrolling new patients. To learn more about a particular study, choose from the list below.

and/or
29 Clinical Trials found
A Phase 2 Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Datopotamab Deruxtecan Alone or With Other Anti-Cancer Drugs in People Endometrial, Ovarian, and Urothelial Cancers
Researchers want to see how well datopotamab deruxtecan (Dato-DXd) works alone and with other drugs against cancer. The people in this study have endometrial, ovarian, or urothelial cancer that has metastasized (spread).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Raludotatug Deruxtecan in People With Advanced Solid Tumors
Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of VS-6766 and Defactinib in People with Advanced Mesonephric Gynecologic Cancer
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Avutometinib Plus Defactinib Versus Standard Treatment for People With Low-Grade Serous Ovarian Cancer
In this study, researchers are comparing a combination of two new drugs with standard treatment for ovarian cancer. The two drugs are avutometinib and defactinib. The people in this study have low-grade serous ovarian cancer that came back after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus No HIPEC followed by Niraparib in People Newly Diagnosed With Advanced Ovarian Cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC) involves giving heated chemotherapy directly into the belly immediately after surgery to remove an abdominal cancer. Researchers are doing this study to see if HIPEC improves outcomes in people with ovarian cancer. The people in this study have newly diagnosed stage 3 or 4 ovarian cancer.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Researchers are assessing maintenance therapy with olaparib given for 1 or 2 years, with or without bevacizumab, to treat ovarian cancer. The people in this study have stage 3 or 4 ovarian cancer with certain genetic mutations (changes).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced non-HRD-Positive Ovarian Cancer…
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I/II Study of REGN4018 Given Alone or in Combination with Cemiplimab in Women with Recurrent Ovarian Cancer
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I/II Study of REGN5668 plus Cemiplimab or REGN4018 in People with Recurrent Ovarian Cancer
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau